Inhibace (Cilazapril)

Cilazapril blocks the angiotensin‑converting enzyme, which stops the conversion of angiotensin I into angiotensin II. This reduces vasoconstriction, lowers aldosterone release, promotes sodium excretion, and ultimately leads to lower systemic blood pressure and decreased cardiac workload.

The dose of Inhibace is individualized by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and overall clinical status. Only a qualified healthcare professional should determine the appropriate regimen.

Cilazapril is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy, and breastfeeding is not recommended because the drug can be excreted in milk and may affect the infant.

To order Inhibace, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inhibace (cilazapril) belongs to the same class as enalapril, lisinopril and ramipril. All share a similar mechanism of blocking ACE, but they differ in pharmacokinetic profiles, dosing frequency and potency. Cilazapril is often chosen for its once‑daily dosing and favorable tolerability in many patients.

Store Inhibace at room temperature, below 25 °C, in the original blister or bottle. Keep the product away from moisture, heat and direct sunlight to maintain its stability and potency.

Inhibace is supplied as an oral tablet that should be swallowed whole with a glass of water. It is usually taken once daily, but the exact timing and any food considerations are determined by the prescribing clinician.

The most serious adverse events include angioedema (swelling of the face, lips, tongue or airway), severe hypotension (especially after the first dose), and acute renal impairment. Patients should seek immediate medical attention if any of these symptoms occur.

Inhibace is contraindicated in patients with a known history of angioedema related to ACE‑inhibitor therapy, in pregnant women, and in individuals with severe renal artery stenosis or marked renal impairment. Caution is also advised for patients with hyperkalaemia or those taking potassium‑increasing drugs.